ABSTRACT
Objective To explore the clinical effect and safety of Suhexiang Pills () in the treatment of patients with tachycardia after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Methods A total of 138 patients with tachycardia after SARS-CoV-2 infection admitted to eight hospitals such as 971st Hospital of the PLA Navy, Changzhou Second People's Hospital, Xuzhou First People's Hospital, Henan Provincial People's Hospital, Henan Chest Hospital from February 2023 to March 2023 were randomly divided into control group and treatment group, with 87 patients in the treatment group and 51 in the control group. Patients in the control group were po administered with betaloc, once a day, and the initial dose was 23.75 mg, adjusted in time according to the patient's heart rate. Patients in the treatment group were po administered with Suhexiang Pills, 1 pill/time, twice daily. Patients in two groups were treated for 7 d. The clinical efficacy of the two groups was observed, and the heart rate and cardiac function indexes, RR interval, blood oxygen saturation and adverse reactions were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 98.85%, and the total effective rate of the control group was 90.20%, and the difference between the two groups was statistically significant (P < 0.05). After treatment, heart rates were significantly decreased in both groups (P < 0.05), and the heart rates of the treatment group were significantly better than those of the control group (P < 0.05) on the 7th day of treatment. After treatment, the level of left ventricular ejection fraction (LVEF) in both groups was significantly higher than that before treatment (P < 0.05), and there was statistical difference between the treatment group and the control group (P < 0.05). The levels of left ventricular end diastolic dimension (LVEDD) and left ventricular end-systolic diameter (LVESD) in the treatment group significantly decreased than that before treatment (P < 0.05), and there was no statistical difference compared with the control group (P > 0.05). After treatment, the maximum RR interval in both groups reached the normal range on the third day, and the treatment group was significantly better than the control group (P < 0.05). Blood oxygen saturation of the treatment group was significantly increased on the 7th day of treatment compared with before treatment (P < 0.05), but there was no statistical significance between the two groups (P > 0.05). There was no significant difference in the total incidence of adverse events between the two groups (P > 0.05). Conclusion Suhexiang Pills decrease heart rates in patients with tachycardia after SARS-CoV-2 infection, which was equivalent to the effect of western medicine, and can protect heart, improve heart function to a certain extent.Copyright © 2023 Editorial Office of Chinese Traditional and Herbal Drugs. All rights reserved.
ABSTRACT
[] Objective: To analyze relevant literature on Lianhua Qingwen preparations and clarify the research advances and hot spots in this field,so as to provide references for clinical rational application and further research. Method: Literature related to Lianhua Qingwen preparations in the recent 10 years was retrieved from six databases,including China National Knowledge Infrastructure(CNKI),VIP,Wanfang Data, PubMed,and Web of Science,followed by management and analysis by NoteExpress and CiteSpace. Result: Finally,344 and 76 Chinese and English research articles were included,and the number of publications increased in recent years. The research articles were published in 162 Chinese and 48 English journals. Shijiazhuang Yiling Pharmaceutical Co.,Ltd. and Guangzhou Medical University were institutions with the largest number of Chinese and English publications,respectively. LIU Minyan was the author who had published the most articles. Keywords with high frequency included clinical efficacy,Lianhua Qingwen,inflammatory factors,traditional Chinese medicine,and coronavirus disease-2019(COVID-19). Nineteen clusters,including clinical efficacy,Chinese medicine,Lianhua Qingwen,COVID-19,and influenza A virus,and 47 emergent keywords,including herpes zoster,pneumonia,inflammatory factors,influenza,and gut microbiota,were generated. Conclusion:Cooperation and exchanges in this field are insufficient. Research focuses on the clinical efficacy of Lianhua Qingwen in the treatment of COVID-19 and other diseases,pharmacological action and mechanism of antiviral drugs,and micro-mechanism research focuses on related pathways and target proteins,as well as the combination of Chinese and western medicines.Copyright © 2023, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.
ABSTRACT
The study sought to explore the motivating factors for and barriers to the uptake of the coronavirus disease 2019 (COVID-19) vaccine in Zambia and recommend possible ways of addressing the challenges. The study used a qualitative case study approach, employing online media platforms as sources of data. Thematic analysis was to identify topics from posts, with each topic further grouped into themes. Motivating factors to vaccine uptake include an increase in reported cases of COVID-19, accessibility, and availability of vaccines, vaccine certificates required to travel, and credible sources of information. Barriers to uptake include lack of information, concerns about the safety of the vaccine, mistrust in Western medicine, lack of belief in conventional medicine versus belief in God, confusing information about eligibility, and belief that public figures used in the campaigns were not receiving the vaccine. Some of the strategies to encourage vaccination included the involvement of local scientists, demand generation through media platforms, community sensitization, vaccine materials, and creating an enabling environment for community involvement. The social media interactions on the COVID-19 vaccine revealed several factors that impede the uptake of the vaccine and encourage uptake. However, stakeholders' involvement in scaling up vaccination programs was reported to be one of the effective strategies to increase vaccine uptake in Zambia.Copyright © 2022 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license.
ABSTRACT
[] Objective: To analyze relevant literature on Lianhua Qingwen preparations and clarify the research advances and hot spots in this field,so as to provide references for clinical rational application and further research. Method: Literature related to Lianhua Qingwen preparations in the recent 10 years was retrieved from six databases,including China National Knowledge Infrastructure(CNKI),VIP,Wanfang Data, PubMed,and Web of Science,followed by management and analysis by NoteExpress and CiteSpace. Result: Finally,344 and 76 Chinese and English research articles were included,and the number of publications increased in recent years. The research articles were published in 162 Chinese and 48 English journals. Shijiazhuang Yiling Pharmaceutical Co.,Ltd. and Guangzhou Medical University were institutions with the largest number of Chinese and English publications,respectively. LIU Minyan was the author who had published the most articles. Keywords with high frequency included clinical efficacy,Lianhua Qingwen,inflammatory factors,traditional Chinese medicine,and coronavirus disease-2019(COVID-19). Nineteen clusters,including clinical efficacy,Chinese medicine,Lianhua Qingwen,COVID-19,and influenza A virus,and 47 emergent keywords,including herpes zoster,pneumonia,inflammatory factors,influenza,and gut microbiota,were generated. Conclusion:Cooperation and exchanges in this field are insufficient. Research focuses on the clinical efficacy of Lianhua Qingwen in the treatment of COVID-19 and other diseases,pharmacological action and mechanism of antiviral drugs,and micro-mechanism research focuses on related pathways and target proteins,as well as the combination of Chinese and western medicines.Copyright © 2023, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.
ABSTRACT
[] Objective: To analyze relevant literature on Lianhua Qingwen preparations and clarify the research advances and hot spots in this field,so as to provide references for clinical rational application and further research. Method: Literature related to Lianhua Qingwen preparations in the recent 10 years was retrieved from six databases,including China National Knowledge Infrastructure(CNKI),VIP,Wanfang Data, PubMed,and Web of Science,followed by management and analysis by NoteExpress and CiteSpace. Result: Finally,344 and 76 Chinese and English research articles were included,and the number of publications increased in recent years. The research articles were published in 162 Chinese and 48 English journals. Shijiazhuang Yiling Pharmaceutical Co.,Ltd. and Guangzhou Medical University were institutions with the largest number of Chinese and English publications,respectively. LIU Minyan was the author who had published the most articles. Keywords with high frequency included clinical efficacy,Lianhua Qingwen,inflammatory factors,traditional Chinese medicine,and coronavirus disease-2019(COVID-19). Nineteen clusters,including clinical efficacy,Chinese medicine,Lianhua Qingwen,COVID-19,and influenza A virus,and 47 emergent keywords,including herpes zoster,pneumonia,inflammatory factors,influenza,and gut microbiota,were generated. Conclusion:Cooperation and exchanges in this field are insufficient. Research focuses on the clinical efficacy of Lianhua Qingwen in the treatment of COVID-19 and other diseases,pharmacological action and mechanism of antiviral drugs,and micro-mechanism research focuses on related pathways and target proteins,as well as the combination of Chinese and western medicines.Copyright © 2023, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.
ABSTRACT
Objective In light of the comprehensively implemented reform of medical insurance payments, this study analyzed the impact of the payment intervention and COVID-19 pandemic on hospitalization expenses for identical diseases between traditional Chinese medicine (TCM) and Western medicine hospitals, to provide evidence to promote high-quality coordinated development of hospitals and insurance while reducing patient load. Methods From January 2014 to December 2020, we gathered data including 9 900 individual medical records of woman-related malignant tumors (WMT) from all 23 public hospitals in a district of Shanghai. We developed an interrupted time-series analysis model based on the above two interventions, to compare the inpatient average per-time expenses between different hospitals and different groups. Results The average per-time expenses of WMT in Western hospitals changed from rising to declining after the policy intervention, and increased again during the pandemic. In TCM hospitals, the expenses continued to increase and fluctuated after the pandemic. Conclusion The policy intervention has achieved a good effect on controlling the cost of Western hospitals, rather than the significant increase in TCM hospitals. Meanwhile, the COVID-19 pandemic has had a significant impact on hospitalization expenses. It's urgent to develop a payment model that fits the development and characteristics of TCM, to control the unreasonable growth of expenses. Moreover, the financial compensation methods and supervision mechanism of public hospitals should be improved to effectively resist the threat of public health emergencies for the development of hospitals and the legitimate rights of patients.Copyright © 2023 West China University of Medical Science. All rights reserved.
ABSTRACT
Objective In light of the comprehensively implemented reform of medical insurance payments, this study analyzed the impact of the payment intervention and COVID-19 pandemic on hospitalization expenses for identical diseases between traditional Chinese medicine (TCM) and Western medicine hospitals, to provide evidence to promote high-quality coordinated development of hospitals and insurance while reducing patient load. Methods From January 2014 to December 2020, we gathered data including 9 900 individual medical records of woman-related malignant tumors (WMT) from all 23 public hospitals in a district of Shanghai. We developed an interrupted time-series analysis model based on the above two interventions, to compare the inpatient average per-time expenses between different hospitals and different groups. Results The average per-time expenses of WMT in Western hospitals changed from rising to declining after the policy intervention, and increased again during the pandemic. In TCM hospitals, the expenses continued to increase and fluctuated after the pandemic. Conclusion The policy intervention has achieved a good effect on controlling the cost of Western hospitals, rather than the significant increase in TCM hospitals. Meanwhile, the COVID-19 pandemic has had a significant impact on hospitalization expenses. It's urgent to develop a payment model that fits the development and characteristics of TCM, to control the unreasonable growth of expenses. Moreover, the financial compensation methods and supervision mechanism of public hospitals should be improved to effectively resist the threat of public health emergencies for the development of hospitals and the legitimate rights of patients.Copyright © 2023 West China University of Medical Science. All rights reserved.
ABSTRACT
Backgroud: The outbreak of COVID-19 has brought unprecedented perils to human health and raised public health concerns in more than two hundred countries. Safe and effective treatment scheme is needed urgently. Objective(s): To evaluate the effects of integratedTCM and western medicine treatment scheme on COVID-19. Method(s): A single-armed clinical trial was carried out in Hangzhou Xixi Hospital, an affiliated hospital with Zhejiang Chinese Medical University. 102 confirmed cases were screened out from 725 suspected cases and 93 of them were treated with integrated TCM and western medicine treatment scheme. Result(s): 83 cases were cured, 5 cases deteriorated, and 5 cases withdrew from the study. No deaths were reported. The mean relief time of fever, cough, diarrhea, and fatigue were (4.78 +/- 4.61) days, (7.22 +/- 4.99) days, (5.28 +/- 3.39) days, and (5.28 +/- 3.39) days, respectively. It took (14.84 +/- 5.50) days for SARS-CoV-2 by nucleic acid amplification-based testing to turn negative. Multivariable cox regression analysis revealed that age, BMI, PISCT, BPC, AST, CK, BS, and UPRO were independent risk factors for COVID-19 treatment. Conclusion(s): Our study suggested that integrated TCM and western medicine treatment scheme was effective for COVID-19.Copyright © 2021
ABSTRACT
Since the dawn of humankind, humans have relied on plant-based medicines for the majority of their health and disease needs. The rapid and increasing rise in the worldwide use of herbal medicines in recent decades suggests botanical medicines, both traditional and modern, fulfill a therapeutic niche not adequately addressed in modern health care delivery systems. At the same time, there is a propensity, predominantly in developed, but also developing nations, to develop herbal medicines in the same manner as modern chemically characterized drugs. This trend is driven partly by a belief that the same regulatory requirements that are applied to modern pharmaceuticals should be applied to herbal medicines and partly by economics, a subject not often discussed. © 2022 Elsevier Inc. All rights reserved.
ABSTRACT
The coronavirus disease 2019 (COVID-19) has become a global public health problem due to its highly contagious nature. This article aims to discuss the current situation of traditional Chinese medicine in the prevention and treatment of COVID-19, and to provide a basis for traditional Chinese medicine research and scientific and standardized treatment of COVID-19. In this article, the etiology, pathogenesis, treatment plan and research progress were summarized, analyzed and concluded by retrieving and reviewing the literature and clinical reports related to the prevention and treatment of COVID-19 with traditional Chinese medicine. Traditional Chinese medicine has obvious effects in the prevention and treatment of COVID-19, improvement of clinical symptoms, and control of disease progression, which had the unique advantages of mild curative efficacy and safety. It has important practical significance in relieving patients' early symptoms and reducing the incidence of progression from mild to severe, and had great potential for development in the treatment of COVID-19. The traditional Chinese medicine intervention and the formulation of diagnosis and treatment plans for the COVID-19 need to be continuously optimized and improved. Scientific and rational application of traditional Chinese medicine to prevent and treat COVID-19, optimization diagnosis and treatment programs, and in-depth exploration of pharmacological mechanisms, especially the provide reference for early intervention of new coronavirus pneumonia by traditional Chinese medicine, the control of disease progression in the middle stage, and improve prognosis in the late stage with Western medicine. © 2022 Editorial Office of Chinese Journal of Schistosomiasis Control. All rights reserved.
ABSTRACT
Health systems and their trends are continually evolving with advanced research on new tools and techniques. Since every health system has its limitations, there is a requirement for the integration of different medical systems to better serve mankind. In this direction, a practitioner of modern medicine should take into consideration traditional medicine practices, while the traditional medicine practitioner should also integrate the beneficial strategies of modern medicine. In spite of different approaches, the aim of all these medical systems is the same, which is to serve mankind by treating various health problems. Although traditional medicine has the potential to treat a variety of diseases, its acceptance by the global community is less than that of modern medicine due to inadequate scientific validation of its therapeutic benefits. In recent years, many new diseases have emerged, perhaps due to changes in geography, environment, weather conditions, and soil composition. A complete treatment of such diseases is a challenge for all medical practitioners, whether belonging to modern or traditional medicine. Therefore, an in-depth multidisciplinary research is needed to find an effective therapeutic strategy by connecting modern and traditional medical systems with biomedical sciences. In this direction, biotechnology can play an important role in developing a diagnostic method and treatment protocol. The present review provides an overview of the available Ayurvedic treatment options and future possibilities in which biotechnology may assist as a service provider. Copyright © 2023 Bentham Science Publishers.
ABSTRACT
OBJECTIVE: To systematically review the clinical efficacy and safety of Chinese herbal medicine (CHM) with and without Western medicine (WM) for different severity of COVID-19. METHODS: CNKI, PubMed, Wanfang Database, ClinicalTrails.gov, Embase, ChiCTR and ICTRP were searched from 01 Jan, 2020 to 30 Jun, 2021. Two authors independently assessed all the randomized clinical trials (RCTs) for trial inclusion, data extraction and quality assessment. Meta-analysis was conducted using Review Manager software (RevMan 5.4.1). Evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Primary outcomes included total effectiveness rate. Secondary outcomes included improvements in symptom improvement and total adverse event rate. Different severity of COVID-19 patients was assessed in subgroup analysis. This study was registered with INPLASY, INPLASY202210072. RESULTS: 22 high quality RCTs involving 1789 participants were included. There were no trial used CHM alone nor compare placebo or no treatment. Compared with WM, combined CHM and WM (CHM-WM) treatment showed higher total effectiveness rate, lower symptom scores of fever, cough, fatigue, dry throat and pharyngalgia, shorter mean time to viral conversion, better Computerized Tomography (CT) image and blood results, fewer total adverse events and worse conditions (P < 0.05). Subgroup analysis showed that the total effectiveness rate of combined CHM-WM group was significantly higher than WM group, especially for mild and moderate patients. No significant differences in mortality and adverse events were found between combined CHM-WM and WM treatment. No serious adverse events and long-term outcomes were reported. CONCLUSION: Current evidence supported the therapeutic effects and safety of combined CHM-WM treatment on COVID-19, especially for patients with mild and moderate symptoms. Long-term effects of therapy are worthy in further study.
ABSTRACT
Renaissance in acceptance of the Siddha system of medicine in all over India happened during the current scenario of coronavirus disease-2019 (COVID-19) pandemic. The classical texts of Siddha medicine contain descriptions of the symptoms of COVID-19 as a syndrome like definition that may be correlated with KabaSuram. A 49-year-old female residing at New Delhi who got COVID-19 positive with comorbidity of hypothyroidism treated successfully using an integrative treatment plan (Siddha and Allopathic) as per Government-mandated COVID-19 treatment guidelines. The patient developed symptoms such as fever, sore throat, cold, cough with expectoration, difficulty in breathing, chest congestion, and body ache. Initially the patient took Western Medicine (WM) for five days but the symptoms did not subside. After five days an integrated treatment including Siddha medicine (Internal and external medicines) initiated at In Patient ward, Safdarjung Hospital. The health of the patient improved within 3 days and all her symptoms got relieved within 10 days. After completion of treatment, she tested reverse transcription - polymerase chain reaction (RT-PCR) and it was negative on 14th day. Another patient who was admitted with her got COVID-19 positive turned negative only after 30 days as she missed the integrative medicine by probability. The reported case had a prospective follow-up for six months and found to be free of post-COVID complications. Since, this case report based on a single case which shows a positive outcome is incapable of generalizing the conclusion. Further suitable clinical trials need to be conducted to assess its efficacy. The status of the summary is reported as per CAse REport (CARE) guidelines.
ABSTRACT
Introduction: There is no effective treatment plan for coronavirus disease 2019 (COVID-19). We employed a combination of Chinese and Western medicine treatment for some COVID-19 inpatients. Methods: This study was a prospective cohort study that observed non-critical COVID-19 inpatients. The differences will be observed in the time from admission to two consecutive 2019-nCoV nucleic acid test negatives and the Visual Analog Scale (VAS) score between the two groups. Results: A total of 254 confirmed COVID-19 patients were included in this study. The median time from the admission to two consecutive negative nucleic acid tests was 14 days for the integrated Chinese and Western Medicine (ICWM) group, while the Western Medicine (WM) group was 16 days. Besides, the median VAS score of the ICWM group was 0, which was an average decrease of 2 points compared to the time of admission. Conclusion: For non-critical COVID-19 patients, it was safe and have more benefits to add traditional Chinese medicine decoction based on WM treatment.
ABSTRACT
Although plenty of clinical trials have confirmed the efficacy and safety of integrated traditional Chinese and Western medicine (ITCWM) against COVID-19, the role of ITCWM remains controversial. So we conducted a systematic review and meta-analysis of published studies in eight major databases that report the outcomes of interest in COVID-19 patients receiving ITCWM. RevMan5.4 software was used for meta-analysis, while the quality of RCTs was assessed by the Cochrane risk of bias tool and the retrospective studies were assessed by Newcastle-Ottawa Scale. Eventually, a total of 53 studies with 5425 COVID-19 patients was identified. The meta-analysis results showed that ITCWM was significantly better than western medicine treatment (WMT) alone in the percentage of cases changing to severe/critical [RR = 0.40, 95%CI (0.33, 0.49), p < .00001, I2 = 10%], overall clinical effectiveness [RR = 1.26, 95% CI (1.18, 1.35), p < .00001, I2 = 50%], time to defervescencer [MD = -1.45, 95% CI (-1.82, -1.07), p < .00001, I2 = 83%], disappearing time of cough [MD = -2.11, 95% CI (-2.98, -1.25), p < .00001, I2 = 93%], time of RT-PCR negativity [MD = -3.35, 95% CI (-4.74, -1.95), p < .00001, I2 = 92%], length of hospital stay [MD = -4.05, 95% CI (-5.24, -2.85), p < .00001, I2 = 91%], improvement in CT scan [RR = 1.22, 95% CI (1.17, 1.28), p < .00001, I2 = 46%], TCM syndrome score [MD = -3.95, 95% CI (-5.07, -2.82), p < .00001, I2 = 92%], disappearance rate of fever [RR = 1.23, 95% CI (1.10, 1.38), p < .00001, I2 = 85%], disappearance rate of cough [RR = 1.43, 95% CI (1.25, 1.63), p < .00001, I2 = 60%], level of CRP [MD = -9.23, 95% CI (-10.94, -7.52), p < .00001, I2 = 97%], and WBC [MD = -9.23, 95% CI (-10.94, -7.52), p < .00001, I2 = 97%]. There is no significant difference between ITCWM and WMT in the adverse reaction rate [RR = 0.85, 95% CI(0.71, 1.03), p = .10, I2 = 25%]. Our results showed evidence of clinical efficacy and safety benefit in COVID-19 patients treated with ITCWM. In spite of some limitations, the rapidly developing global pandemic warrants further high-quality and multicenter clinical studies to confirm the contribution of ITCWM.
ABSTRACT
From ancient times to the present, mankind has experienced many infectious diseases, which have mutually affected the development of society and medicine. In this paper, we review various historical and current infectious diseases in a five-period scheme of medical history newly proposed in this paper: (1) Classical Western medicine pioneered by Hippocrates and Galen without the concept of infectious diseases (ancient times to 15th century); (2) traditional Western medicine expanded by the publication of printed medical books and organized medical education (16th to 18th century); (3) early modern medicine transformed by scientific research, including the discovery of pathogenic bacteria (19th century); (4) late modern medicine, suppressing bacterial infectious diseases by antibiotics and elucidating DNA structure as a basis of genetics and molecular biology (20th century, prior to the 1980s); and (5) exact medicine saving human life by in vivo visualization and scientifically verified measures (after the 1990s). The historical perspectives that these five periods provide help us to appreciate ongoing medical issues, such as the present COVID-19 pandemic in particular, and remind us of the tremendous development that medicine and medical treatment have undergone over the years.
ABSTRACT
Since the outbreak of coronavirus disease-2019 (COVID-19), traditional Chinese medicine (TCM) has fully displayed its strength and specialty and has played an important role in the prevention and treatment of the pandemic. Faced with the unexpected development of the pandemic, the Chinese government has responded quickly and attached great importance to the effect of TCM. Comprehensive therapy integrating Chinese and Western medicine has achieved remarkable success. To summarize and introduce the prevention and treatment of COVID-19 with TCM, this article covers the perspectives of policy guideline issue, clinical diagnosis participation, and scientific research progress. © 2020 Chinese Medicine and Culture. All rights reserved.
ABSTRACT
OBJECTIVE: To evaluate the effectiveness and safety of Baidu Jieduan Granules (BDJDG) to treat common type coronavirus disease 2019 (COVID-19). METHODS: This multicenter, retrospective, and observational clinical trial included 230 common COVID-19 patients in Leishenshan, Huangshi, and Laohekou Hospitals in Wuhan from January 21 to March 26, 2020. The included patients were further divided into two subgroups according to the use of supplemental oxygen, mild and moderate groups. During the first 14 d of hospitalization, all patients were administered BDJDG combined with conventional Western medicine, and observed for continuous 28 d. Primary outcomes were disease progression rate and discharge rate. Secondary outcomes included negative conversion time of nucleic acid, hospitalization duration, clinical symptom subsidence time, and symptom regression rate. RESULTS: A total of 230 common COVID-19 patients were analyzed (138 in moderate group and 92 in mild group). By day 28, the disease progression rate was 4.3% and the discharge rate was 95.7%. All mild cases recovered and were discharged from hospital. The median negative conversion time of nucleic acid of all 230 COVID-19 patients was 12 d [inter-quartile range (IQR) 3.5-17], the median hospitalization duration was 15 d (IQR 12-20). The median time to fever, cough, and fatigue recovery was 4 d (IQR 2-6), 8 d (IQR 5-12), and 8 d (IQR 5-11). The recovery rate of fever, cough, and fatigue was 94.6%, 90.5%, and 93.5%. The median time to clinical improvement was 12 d (IQR 10-17). Compared with the baseline, total leukocyte counts, neutrophil counts, lymphocyte counts, and platelet counts were increased significantly on days 7 and 14 (P<0.01). C-reactive protein markedly increased on day 3 and significantly decreased on days 7 and 14 (P<0.01). No serious adverse events occurred during treatment. CONCLUSION: BDJDG may be effective and safe for treatment of common type COVID-19. (Registration No. ChiCTR2000030836).
Subject(s)
COVID-19 Drug Treatment , Nucleic Acids , C-Reactive Protein , China , Cough/drug therapy , Disease Progression , Fatigue , Fever , Humans , Oxygen , Retrospective Studies , SARS-CoV-2 , Treatment OutcomeABSTRACT
Objectives: Price and volume changing trends of medicines has become a focus of attention from a global perspective. This is especially true in China because of a series of drug reforms initiated in recent years, such as nationwide bulk procurement of medicines. This study aims to compile the drug purchase price index and volume index, which is applied to present their dynamic changes of prices and volumes and to reflect overall supply of medicines in Shanghai. Methods: Based on the database of Shanghai Sunshine Medical Procurement All-In-One, Laspeyres price index and Pascal purchase volume index was calculated monthly and annually by using Western medicines purchase records during 2018 and 2020, which were uploaded from all the medical institutions in Shanghai. Results: Compared with the previous year, the price index of medicines and those covered by the basic medical insurance schemes were 93.3 and 93.1 respectively in 2019, while they were 95.8 and 95.6 in 2020. Monthly price index declined significantly in March 2019, April 2020 and November 2020, for the new purchase prices were implemented in these months. Meanwhile, annual procurement volume had limited changes with monthly fluctuations. Prices of those drugs not covered by the medical insurance fell slightly, and their volumes dropped sharply after the COVID-19 outbreak. Conclusions: Prices of medicines maintained a downward trend in stability with limited procurement volume changes in Shanghai. The empirical case of price index and volume index of medicines in Shanghai has verified the feasibility of its application in drug price monitoring and management. It has also provided strong evidence for policy decision-making and evaluation.